Shots:

• The company has completed the patient enrolment in the (SPHERE Per-AF) trial evaluating Sphere-9 pulsed field (PF) in 477 patients with persistent AF across 23 centers in the US & EU. Patients will now be followed for 12mos.
• Sphere-9 catheter can deliver both RF & PF energies for ablation, combining mapping, navigation & therapeutic capabilities providing users with more options when performing ablation procedures
• The study focuses to determine the safety and effectiveness of Sphere-9 cardiac ablation and mapping catheter with the Affera cardiac mapping and navigation platform & improve efficiencies by enabling intuitive HD mapping to diagnose arrhythmias with a single catheter

Ref: Medtronic | Image: Medtronic